Long-term follow-up for people previously treated with cilta-cel
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study follows people over time who previously received cilta-cel in a Janssen-sponsored clinical trial. It helps doctors learn about how well the treatment works and how safe it is in the long run.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received at least one dose of cilta-cel (car-t cell therapy) in a Janssen-sponsored clinical study.
- You must be able and willing to sign informed consent for this study.
- You must be a participant from the prior company-sponsored study that used cilta-cel.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks on the long-term safety and how well the body handles the GC012F treatment over time. For people who already had this treatment before, it helps doctors see if the effects last and if there are any late side effects.
This program provides access to an experimental CAR-T cell therapy called cilta-cel for people with multiple myeloma who have run out of other good options. It is designed for those who qualify for the standard treatment but need special handling because their cell product is out of specification.
This study looks at late side effects that may happen after CAR-T therapy (cilta-cel) for multiple myeloma. It aims to better understand these delayed toxicities so doctors can manage them more effectively.
This trial tests a one-time cell therapy called ciltacabtagene autoleucel (a CAR-T treatment) in people who have newly diagnosed multiple myeloma and are not eligible for a stem cell transplant. It aims to see if this treatment is safe and effective as an early therapy.
This trial tests adding total body radiation and a chemotherapy drug (cyclophosphamide) before the standard Carvykti cell therapy for multiple myeloma patients who have kidney problems. The goal is to see if this approach is safe and effective for people with reduced kidney function.
This registry study will follow people who have received the CAR T-cell therapy equecabtagene autoleucel to monitor their long-term health and outcomes. It is open to those who completed or withdrew from an earlier study of this treatment.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.